1. Home
  2. SUPX vs AKBA Comparison

SUPX vs AKBA Comparison

Compare SUPX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super X AI Technology Limited Ordinary Shares

SUPX

Super X AI Technology Limited Ordinary Shares

HOLD

Current Price

$6.97

Market Cap

302.7M

Sector

N/A

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.89

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPX
AKBA
Founded
2021
2007
Country
Singapore
United States
Employees
40
194
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
302.7M
248.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
SUPX
AKBA
Price
$6.97
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $4.67
AVG Volume (30 Days)
815.1K
★ 6.3M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.61
$0.81
52 Week High
$76.00
$3.19

Technical Indicators

Market Signals
Indicator
SUPX
AKBA
Relative Strength Index (RSI) 43.19 40.12
Support Level $5.61 $0.85
Resistance Level $7.60 $0.98
Average True Range (ATR) 0.75 0.05
MACD -0.16 -0.00
Stochastic Oscillator 7.52 1.40

Price Performance

Historical Comparison
SUPX
AKBA

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: